UroGen Pharma
URGN
81 hedge funds and large institutions have $262M invested in UroGen Pharma in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 26 reducing their positions, and 9 closing their positions.
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
1% more funds holding
Funds holding: 80 → 81 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 26
2.34% less ownership
Funds ownership: 68.21% → 65.87% (-2.3%)
9% less capital invested
Capital invested by funds: $289M → $262M (-$27.2M)
59% less call options, than puts
Call options by funds: $2.05M | Put options by funds: $4.97M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$2.14M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$1.2M |
| 3 |
BlackRock
New York
|
+$920K |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$829K |
| 5 |
Renaissance Technologies
New York
|
+$687K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$8.89M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.25M |
| 3 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$1.72M |
| 4 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$934K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$892K |
URGN Hedge Fund Activity: Q4 2020 in Review
81 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2020, worth a combined $262M — down 9.4% from $289M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new URGN positions and 9 closed out — a net gain of 1 holder — while 25 added to existing stakes and 26 trimmed.
The largest buyer was Rice Hall James & Associates, opening a new position worth an estimated $2.14M. The largest seller was Artisan Partners, exiting entirely with an estimated $8.89M sold.
- 81 institutional investors held UroGen Pharma (URGN) as of Q4 2020, up from 80 in Q3 2020.
- Funds reported $262M of UroGen Pharma stock for Q4 2020, down 9.4% quarter-over-quarter.
- 10 funds opened new UroGen Pharma positions in Q4 2020 and 9 closed out, a net change of +1 holder.
- The largest UroGen Pharma buyer in Q4 2020 was Rice Hall James & Associates, an estimated $2.14M added.
- The largest UroGen Pharma seller in Q4 2020 was Artisan Partners, an estimated $8.89M sold.
Based on aggregated 13F filings for Q4 2020.